Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
DRMA
DRMA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DRMA News
OceanFirst Financial Corp. Announces $579 Million All-Stock Acquisition of Flushing, Shares Drop 7.4%
Dec 30 2025
Benzinga
Fonar Corp (FONR) Signs Definitive Agreement for Take-Private Sale, Shares Surge 24.5%
Dec 30 2025
Benzinga
TEN Holdings Inc. Announces $2.25 Million Private Placement, Shares Surge 16.31%
Dec 30 2025
Benzinga
TEN Holdings Inc. Raises $2.25M in Private Placement, Shares Surge 17%
Dec 30 2025
Benzinga
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
Dec 26 2025
Benzinga
Dermata Therapeutics (DRMA) Raises $4.1M by Issuing 2.02M Shares at $2.04 Each
Dec 26 2025
NASDAQ.COM
Dermata Therapeutics Secures $12.4 Million in Private Placement Financing
Dec 24 2025
Benzinga
Dermata Therapeutics Set to Introduce First Over-the-Counter Acne Kit by Mid-2026
Dec 08 2025
NASDAQ.COM
Agenda for Life Science Virtual Investor Forum Set for September 18th
Sep 16 2025
Globenewswire
Dermata Therapeutics to Showcase at the Life Sciences Virtual Investor Forum on September 18th
Sep 16 2025
Globenewswire
Maxim Group Reaffirms Buy Rating for Dermata Therapeutics, Adjusts Price Target to $10
Aug 21 2025
Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Mar 28 2025
Benzinga
US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets'
Mar 28 2025
Benzinga
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results
Mar 27 2025
Benzinga
Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
Mar 04 2025
Newsfilter
Dermata Therapeutics announces last patient visit in Phase 3 acne trial
Mar 04 2025
Business Insider
Show More News
